Physician profile
Robert C Scott
NPI 1801919147
$4,094.43
in general payments reported to CMS, 2019-2025
17 companies · $714 in 2025
The $714 reported for 2025 was less than what a typical Advanced Heart Failure and Transplant Cardiology provider received nationally (typical 2025 total: $1,046).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $183 · 2020: $124 · 2021: $550 · 2022: $702 · 2023: $1,316 · 2024: $506 · 2025: $714.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,901 · Travel and Lodging: $635.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,901.41 |
| Travel and Lodging | $634.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,200.53 | 2019-2024 | |
| Ancora Heart, INC. | $690.76 | 2023 | Accucinch |
| Abbott Laboratories | $594.47 | 2020-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems, Xience Skypoint |
| Abiomed | $481.46 | 2019-2025 | Impella |
| Boehringer Ingelheim Pharmaceuticals, INC. | $355.11 | 2021-2025 | |
| Eurofins Viracor, LLC | $154.65 | 2022-2025 | |
| Actelion Pharmaceuticals US, INC. | $146.37 | 2023-2025 | Opsynvi, Uptravi |
| E.R. Squibb & Sons, L.L.C. | $107.86 | 2022-2025 | Camzyos |
| Medtronic Vascular, INC. | $88.96 | 2019-2020 | |
| Endotronix, INC. | $48.38 | 2020-2024 | Cordella Pulomonary Artery Pressure Sensor |
| Alnylam Pharmaceuticals INC. | $44.10 | 2025 | Amvuttra |
| Sobi, INC | $40.02 | 2021 | |
| Novo Nordisk INC | $39.69 | 2025 | |
| Paragonix Technologies, INC. | $33.38 | 2024 | Sherpapak, Liverguard, Pancreaspak |
| Boston Scientific Corporation | $24.04 | 2023 | Lux-Dx Insertable Cardiac Monitor |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fidia Pharma USA INC. | $23.69 | 2024 | Hymovis |
| Scpharmaceuticals INC. | $20.96 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Scott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.